Study of pirtobrutinib for CLL or SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of CLL or SLL.
- If you have had previous treatment, you must have had 1 to 3 prior treatments and taken a covalent BTK inhibitor.
- If you have never been treated, you must have a 17p deletion (a specific genetic change).
- Your cancer must need treatment based on standard guidelines.
- You must be able to swallow oral pills and have a good daily performance level (ECOG 0-2).
- You cannot have had a BTK degrader or noncovalent BTK inhibitor before, or have certain other cancers, serious bleeding from a BTK inhibitor, or Richter's transformation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares two oral medicines—pirtobrutinib and ibrutinib—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It’s designed to see which drug works better and is easier to take, especially for people with a specific genetic change in the cancer (17p deletion).
This trial tests a new drug (BGB-16673) against another drug (pirtobrutinib) for people with CLL or SLL that hasn't responded to or has come back after a prior BTK inhibitor treatment. The goal is to see which drug is more effective and safe.
This study tests a new drug called NX-5948 against an existing drug (pirtobrutinib) for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to a previous BTK inhibitor treatment. The goal is to see if NX-5948 works better or is safer for this hard-to-treat situation.
This trial tests two oral targeted drugs—pirtobrutinib and venetoclax—for people with CLL or SLL whose disease has continued to grow despite taking a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib). The goal is to see if this combination can control the cancer when a BTK inhibitor alone is no longer working.
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
This trial continues treatment with the drug pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already in another study. It is not open to new patients.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.